Even AML samples from favorable risk groups like CBF AML, NPM1-mutated/FLT3 wild type, or CEBPA-mutated AML, that are difficult to engraft in previous immunocompromised strains, were capable of engrafting in NSGS mice (177, 178). This evidence concerns the gene CEBPA and acute myeloid leukemia.